Xilio Therapeutics Inc (XLO)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$9.00-0.22%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · XLO
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -81.5% |
| Our one-year growth estimate | diamond | -48.6% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 32.8 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
XLO — director transition
Dated 2026-04-16
Director — Cheryl R. Blanchard, Ph.D.: Dr. Cheryl R. Blanchard was elected as a Class III director and appointed to the Compensation Committee and Audit Committee, succeeding Christina Rossi.
Why it matters: The IND submission is a key step for XTX501's development. It indicates progress in Xilio's pipeline.
Supportive ifXilio submits the IND application for XTX501 by mid-2026 as planned.
Worry ifThe IND submission for XTX501 is delayed beyond mid-2026.
Why it matters: Updates on cash runway can show if Xilio can pay for its work.
Watch forManagement says they have enough cash until early 2028. They do not need more money.
Also watch forManagement says cash runway is shorter than expected. New money is needed before early 2028.
Why it matters: If sector growth returns, it could boost feelings and results for Xilio.
Supportive ifHealth Care sector revenue growth returns to 10% or more.
Worry ifHealth Care sector revenue growth slows down below 10%.
Why it matters: Updates on cash burn will indicate if Xilio can fund operations through 2027. This is key for long-term viability.
Worry ifCash burn rate decreases or remains stable in Q2 earnings.
Less concerning ifCash burn rate increases significantly in Q2 earnings.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$113 on $10,000 · ±1.1% | How much price usually moves either way. |
| Bad day | $461 loss on $10,000 · 4.6% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,090 loss on $10,000 · 40.9% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Maintaining revenue growth is essential for Xilio's financial health. A decline could signal deeper issues.
Worry ifQ2 2026 revenue shows growth compared to Q1 2026's $12.65 million.
Less concerning ifQ2 2026 revenue declines compared to Q1 2026's $12.65 million.
Why it matters: Starting the Phase 1 trial for XTX501 is a key step in Xilio's drug development. It shows progress in their pipeline and could attract investor interest.
Supportive ifXilio announces the initiation of the Phase 1 trial for XTX501 in patients with metastatic NSCLC.
Worry ifXilio delays the Phase 1 trial initiation beyond the second half of 2026.
Why it matters: Board changes can affect the company's direction and how investors feel.
Watch forAnnouncement of new board members or changes in board roles within the next quarter.
Also watch forNo new board member announcements or changes in roles within the next quarter.
Why it matters: Changes in leadership can change company strategy and performance. The new director may bring shifts.
Watch forLook for strong performance numbers or news after the director changes.
Also watch forBad performance numbers or unclear strategy after the change.
Why it matters: Better revenue growth shows the company is still growing.
Supportive ifQ2 revenue growth above $12.65M, showing a positive trend compared to Q1.
Worry ifQ2 revenue growth below $12.65M, continuing the declining trend.
Why it matters: Good data for XTX601 could boost its market chance and attract investors.
Supportive ifThe company shares good news about XTX601's early data. It shows strong anti-tumor effects.
Worry ifThe updates on XTX601 show weak results or no important findings.
Why it matters: Submitting INDs for these programs shows Xilio's focus on its pipeline. This could lead to future revenue.
Supportive ifXilio submits IND applications for the CLDN18.2 and PSMA+STEAP1 programs in the second half of 2027.
Worry ifXilio announces a delay in the IND submissions for these programs beyond 2027.
Why it matters: Growth in collaboration revenue shows Xilio can make money from its partnerships. This is key for funding operations.
Supportive ifCollaboration and license revenue goes up to more than $18.7 million in Q3 2026.
Worry ifCollaboration and license revenue drops to less than $18.7 million in Q3 2026.
Why it matters: Updates on cash runway help us see if Xilio can fund operations. This includes clinical trials through early 2028.
Watch forXilio confirms cash runway extends into early 2028 with no funding issues.
Also watch forXilio changes cash runway guidance. This shows possible funding issues before early 2028.